Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Last revision Both sides next revision
ms [2017/04/18 09:41]
sflitman [Multiple Sclerosis]
ms [2018/11/18 11:14]
sflitman [Multiple Sclerosis]
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-| Relapsing-Remitting Multiple Sclerosis |  B-cell depleting once-monthly subcutaneous injection vs. Aubagio |  III  |  Yes  |  50%  |  12 months ​ |  Yes  | +| Relapsing-Remitting Multiple Sclerosis |  Novel oral agent vs. Tecfidera ​ |  III  |  Yes  |  50%  |  ​11 weeks  ​|  ​96 weeks  |
-| Relapsing-Remitting Multiple Sclerosis |  Novel oral agent vs. Tecfidera ​ |  III  |  Yes  |  50%  |  ​12 months ​ ​|  ​Yes  |+
  
  
Print/export
QR Code
QR Code ms (generated for current page)